Streptococcus pneumoniae protein vaccine and preparation method thereof

Abstract

The invention discloses a Streptococcus pneumoniae protein vaccine, which is a Streptococcus pneumoniae capsule saccharide-protein conjugate obtained by covalently linking one or a variety of Streptococcus pneumoniae capsule saccharides and a carrier protein, wherein the carrier protein is lectin. Compared to the Streptococcus pneumoniae protein vaccine in the prior art, the Streptococcus pneumoniae protein vaccine of the present invention has the following advantages that the administration mode of the Streptococcus pneumoniae protein vaccine is intranasal administration, wherein the intranasal administration is convenient and rapid compared to intramuscular injection; the Streptococcus pneumoniae protein vaccine can be used as the commercially available Streptococcus pneumoniae supplementary immunization vaccine; and when the large-scale epidemic situation occurs, the Streptococcus pneumoniae protein vaccine can be temporarily used as the emergency vaccine, and can provide the immunization foundation for the subsequent vaccination of the commercially available Streptococcus pneumoniae vaccine.

Description

technical field [0001] The invention relates to a pneumococcal protein vaccine, in particular to a pneumococcal protein vaccine which can be used for nasal administration. Background technique [0002] The epidemiology of pneumococcal disease [0003] The high morbidity, high fatality rate, antibiotic resistance and serious sequelae of pneumococcal disease (PDs), especially the serious impact of the disease on infants and the elderly, make this disease an important global disease. One of the public health problems, my country is also a country with a high incidence of pneumococcal disease. Streptococcus pneumoniae (SP, also known as Streptococcus pneumoniae, Pneumococcus) belongs to the genus Streptococcus and is a catalase-negative Gram-positive diplococcus. The capsule of the outer cell wall is a special structure of bacteria. A layer of mucus material outside the cell wall of some bacteria can protect bacteria from antibacterial or bactericidal substances and phagocytosi...

AI Technical Summary

Problems solved by technology

[0011] Since polysaccharide vaccines only contain polysaccharide antigens (a T cell-independent antigen), they can stimulate mature B lymphocytes, but not T lymphocytes, and cannot produce immune memory

The immune function of infants under 2 years old is not fully developed, and the immune response to polysaccharides is very poor, so polysaccharide vaccines cannot effectively induce protective immune responses in infants under 2 years old

However, nasal administration of vaccines has problems such as easy absorption, strong mucosal irritation, susceptibility to enzymatic degradation, and inability to maintain sustained-release and long-acting effects. [4,5]

Images